Pharmacoresistance

Handbook of Clinical Neurology

Volumn 108, Issue , 2012, Pages 741-757

  Potschka, Heidrun ^a   Brodie, Martin J ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG RESISTANCE; EPILEPSY; HUMAN; PATHOLOGY; REVIEW;

ANIMALS; ANTICONVULSANTS; BRAIN; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; EPILEPSY; HUMANS;

EID: 84865583192     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52899-5.00025-3     Document Type: Chapter

References (144)

1. Ak H., Ay B., Tanriverdi T., et al. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure 2007, 16:493-503.
2. Anderson G.D., Shen D.D. Where is the evidence that P-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy?. Epilepsia 2007, 48:2372-2374.
3. Annegers J.F., Hauser W.A., Elverback L.R. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979, 20:729-737.
4. Aronica E., Gorter J.A., Jansen G.H., et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003, 118:417-429.
5. Aronica E., Gorter J.A., Ramkema M., et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004, 45:441-451.
6. Arts W.F.M., Brouwer O.F., Peters A.C.B., et al. Course and prognosis of childhood epilepsy: 5year follow-up of the Dutch study of epilepsy in childhood. Brain 2004, 127:1774-1784.
7. Baik E.J., Kim E.J., Lee S.H., et al. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999, 843:118-129.
8. Bankstahl J.P., Kuntner C., Abrahim A., et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med 2008, 49:1328-1335.
9. Baltes S., Gastens A.M., Fedrowitz M., et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52:333-346.
10. Bartmann H., Fuest C., La Fougere C., et al. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010, 51:1780-1790.
11. Basic S., Hajnsek S., Bozina N., et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008, 17:524-530.
12. Bates S.F., Chen C., Robey R., et al. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002, 243:83-96.
13. Bauer B., Hartz A.M., Fricker G., et al. Modulation of P-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood) 2005, 230:118-127.
14. Bauer B., Hartz A.M., Pekcec A., et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008, 73:1444-1453.
15. Berg A.T., Kelly M.M. Defining intractability: comparisons among published definitions. Epilepsia 2006, 47:431-436.
16. Berg A.T., Shinnar S., Levy S.R., et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001, 56:1445-1452.
17. Berg A.T., Langfitt J., Shinnar S., et al. How long does it take for partial epilepsy to become intractable?. Neurology 2003, 60:186-190.
18. Bournissen F.G., Moretti M.E., Juurlink D.N., et al. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009, 50:898-903.
19. Brandt C., Bethmann K., Gastens A.M., et al. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006, 24:202-211.
20. Brodie M.J., Perucca E., Ryvlin P., et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408.
21. Brodie M.J., Barry S.J.E., Bamagous G.A., et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012, 78:1548-1554.
22. Brooks-Kayal A.R., Shumate M.D., Jin H., et al. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med 1998, 4:1166-1172.
23. Callaghan B.C., Anand K., Hesdorffer D., et al. Likelihood of seizure remission in adult population with refractory epilepsy. Ann Neurol 2007, 62:383-389.
24. Camfield C., Camfield P., Gordon K., et al. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 1996, 46:41-44.
25. Catterall W.A. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv Neurol 1999, 79:441-456.
26. Clinckers R., Smolders I., Meurs A., et al. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 2005, 314:725-731.
27. Cockerell O.C., Johnson A.L., Sander J.W.A.S., et al. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet 1995, 346:140-144.
28. Cohen A.S., Lin D.D., Quirk G.L., et al. Dentate granule cell GABA(A) receptors in epileptic hippocampus: enhanced synaptic efficacy and altered pharmacology. Eur J Neurosci 2003, 17:1607-1616.
29. Collaborative Group for the Study of Epilepsy Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia 1992, 33:45-51.
30. Coulter D.A. Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered " epileptic" gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia 2000, 41:S96-S99.
31. Cucullo L., Hossain M., Rapp E., et al. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007, 48:505-516.
32. Darius J., Meyer F.P., Sabel B.A., et al. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol 2000, 52:1043-1047.
33. de Boer A.G., Gaillard P.J. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007, 47:323-355.
34. Dlugos D.J., Sammel M.D., Strom B.L., et al. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001, 57:2259-2264.
35. Dombrowski S.M., Desai S.Y., Marroni M., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42:1501-1506.
36. Duncan J.S., Sander J.W., Sisodiya S.M., et al. Adult epilepsy. Lancet 2006, 367:1087-1100.
37. Ellerkmann R.K., Remy S., Chen J., et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003, 119:323-333.
38. Elsinga P.H., Hendrikse N.H., Bart J., et al. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004, 10:1493-1503.
39. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007, 7:447-459.
40. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004, 25:423-429.
41. Gennuso F., Fernetti C., Tirolo C., et al. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc Natl Acad Sci U S A 2004, 101:2470-2475.
42. Gibbs J.P., Adeyeye M.C., Yang Z., et al. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Res 2004, 58:53-66.
43. Gowers W.R. Epilepsy and Other Chronic Convulsive Diseases 1881, Churchill, London, p. 201.
44. Haerian B.S., Roslan H., Raymond A.A., et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010, 19:339-346.
45. Hendrikse N.H. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des 2000, 6:1653-1668.
46. Hendrikse N.H., Vaalburg W. Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography. Methods 2002, 27:228-233.
47. Hendrikse N.H., Vaalburg W. Imaging of P glycoprotein function in vivo with PET. Novartis Found Symp 2002, 243:137-145. discussion 145-8, 180-5.
48. Hendrikse N.H., Kuipers F., Meijer C., et al. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother Pharmacol. 2004, 54:131-138.
49. Hendrikse N.H., Schinkel A.H., de Vries E.G., et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998, 124:1413-1418.
50. Hitiris N., Mohanraj R., Norrie J., et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75:192-196.
51. Hoffmann K., Löscher W. Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-)rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia 2007, 48:631-645.
52. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
53. Holtman L., van Vliet E.A., Edelbroek P.M., et al. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res 2010, 91:49-56.
54. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996, 93:14164-14169.
55. Jeub M., Beck H., Siep E., et al. Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats. Neuropharmacology 2002, 42:107-116.
56. Jobe P.C. Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav 2003, 4:S14-S24.
57. Kanner A.M., Byrne R., Chicharro A., et al. A lifetime psychiatric history predicts a worse seizure outcome fol lowing temporal lobectomies. Neurology 2009, 72:793-799.
58. Kapur J., Macdonald R.L. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997, 17:7532-7540.
59. Kimchi-Sarfaty C., Oh J.M., Kim I.W., et al. A " silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
60. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001, 47:65-81.
61. Kubota H., Ishihara H., Langmann T., et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006, 68:213-228.
62. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
63. Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia 2001, 42:1255-1260.
64. Kwan P., Brodie M.J. Refractory epilepsy: a progressive intractable but preventable condition?. Seizure 2002, 11:77-84.
65. Kwan P., Brodie M.J. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003, 60:S2-S12.
66. Kwan P., Brodie M.J. Drug treatment of epilepsy: when does it fail and how to optimise its use?. CNS Spectr 2004, 9:110-119.
67. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006, 6:397-406.
68. Kwan P., Brodie M.J. Emerging drugs for epilepsy. Expert Opin Emerg Drugs 2007, 12:407-422.
69. Kwan P., Brodie M.J. Definition of refractory epilepsy: defining the indefinable?. Lancet Neurol 2010, 9:27-29.
70. Kwan P., Arzimanoglou A., Berg A.T., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009, 51:1069-1077.
71. Kwan P., Li H.M., Al-Jufairi E., et al. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010, 39:192-197.
72. La Fougère C., Böning G., Bartmann H., et al. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2010, 15:1406-1415.
73. Langer O., Bauer M., Hammers A., et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007, 48:1774-1784.
74. Lazarowski A.J., Lubieniecki F.J., Camarero S.A., et al. New proteins configure a brain drug resistance map in tuberous sclerosis. Pediatr Neurol. 2006, 34:20-24.
75. Lazarowski A., Massaro M., Schteinschnaider A., et al. Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Ther Drug Monit 2004, 26:44-46.
76. Lee Y.J., Maeda J., Kusuhara H., et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 2006, 316:647-653.
77. Leschziner G., Jorgensen A.L., Andrew T., et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol 2006, 5:668-676.
78. Liu X., Yang Z., Yang J., et al. Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 2007, 53:657-663.
79. Löscher W., Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005, 76:22-76.
80. Löscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005, 6:591-602.
81. Löscher W., Klotz U., Zimprich F., et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009, 59:1-23.
82. Löscher W., Sills G.J. Drug resistance in epilepsy: why is a simple explanation not enough?. Epilepsia 2007, 48:2370-2372.
83. Luciano A.L., Shorvon S.D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007, 62:375-381.
84. Luna-Tortos C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
85. Luurtsema G., Molthoff C.F., Windhorst A.D., et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 2003, 30:747-751.
86. Macdonald B.K., Johnson A.L., Goodridge G.M. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000, 48:833-841.
87. Macphee G.J., McInnes G.T., Thompson G.G., et al. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986, 1:700-703.
88. Marchi N., Guiso G., Rizzi M., et al. A pilot study on brain-to-plasma partition of 10,11-dihydro-10-hydroxy-5 H-dibenzo(b, f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 2005, 46:1613-1619.
89. Marson A.G., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
90. Marson A.G., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblended randomised controlled trial. Lancet 2007, 369:1016-1026.
91. Marzolini C., Paus E., Buclin T., et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
92. Mattson R.H., Cramer J.A., Collins J.F., et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary tonic-clonic seizures. N Engl J Med 1985, 1313:145-151.
93. Mazel M., Clair P., Rousselle C., et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 2001, 12:107-116.
94. Mohanraj R., Brodie M.J. Measuring the efficacy of antiepileptic drugs. Seizure 2003, 12:413-443.
95. Mohanraj R., Brodie M.J. Pharmacological outcomes in newly diagnosed epilepsy. Epil Behav 2005, 6:382-387.
96. Mohanraj R., Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006, 13:277-282.
97. Pallis M., Turzanski J., Higashi Y., et al. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002, 43:1221-1228.
98. Pekcec A., Unkrüer B., Stein V., et al. Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res 2009, 83:144-151. http://www.ncbi.nlm.nih.gov/pubmed/19059762.
99. Pekcec A., Unkrüer B., Schlichtiger J., et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther 2009, 330:939-947.
100. Perucca E. Pharmacoresistance in epilepsy: how should it be defined?. CNS Drugs 1998, 10:171-179.
101. Potschka H. Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics 2010, 11:1427-1438.
102. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?. Epilepsia 2010, 51:1333-1347.
103. Potschka H., Fedrowitz M., Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003, 306:124-131.
104. Potschka H., Volk H.A., Löscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. NeuroReport 2004, 15:1657-1661.
105. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129:18-35.
106. Remy S., Gabriel S., Urban B.W., et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003, 53:469-479.
107. Remy S., Urban B.W., Elger C.E., et al. Anticonvulsant pharmacology of voltage-gated Na+channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003, 17:2648-2658.
108. Rizzi M., Caccia S., Guiso G., et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002, 22:5833-5839.
109. Rogawski M.A., Johnson M.R. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008, 8:127-130.
110. Schaub C., Uebachs M., Beck H. Diminished response of CA1 neurons to antiepileptic drugs in chronic epilepsy. Epilepsia 2007, 48:1339-1350.
111. Schiller Y., Najjar Y. Quantifying response to antiepileptic drugs: effect of post treatment history. Neurology 2008, 70:54-65.
112. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:179-194.
113. Schlichtiger J., Pekcec A., Bartmann H., et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol 2010, 160:1062-1071.
114. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
115. Seegers U., Potschka H., Löscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002, 451:149-155.
116. Semah F., Picot M.C., Adam C., et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence?. Neurology 1998, 51:1256-1262.
117. Sharma V. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjug Chem 2004, 15:1464-1474.
118. Siddiqui A., Kerb R., Weale M.E., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003, 348:1442-1448.
119. Sillanpää M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 1993, 34:930-936.
120. Sillanpää M., Schmidt D. Natural history of treated childhood-onset epilepsy: prospective long-term population-based study. Brain 2006, 129:617-624.
121. Sillanpää M., Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain 2008, 131:938-944.
122. Sisodiya S.M., Heffernan J., Squier M.V. Over-expression of P-glycoprotein in malformations of cortical development. NeuroReport 1999, 10:3437-3441.
123. Sisodiya S.M., Lin W.R., Harding B.N., et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125:22-31.
124. Stephen L.J., Kwan P., Brodie M.J. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?. Epilepsia 2001, 42:357-362.
125. Sun G.C., Werkman T.R., Wadman W.J. Kinetic changes and modulation by carbamazepine on voltage-gated sodium channels in rat CA1 neurons after epilepsy. Acta Pharmacol Sin 2006, 27:1537-1546.
126. Syvanen S., Hooker A., Rahman O., et al. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci 2008, 97:5386-5400.
127. Takemiya T., Maehara M., Matsumura K., et al. Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci Res 2006, 56:103-110.
128. Tate S.K., Depondt C., Sisodiya S.M., et al. Genetic predictors of the maximum doses patients receive during clinical use of the antiepileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 2005, 102:5507-5512.
129. Tate S.K., Sing R., Hung C.C., et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 2006, 16:721-726.
130. Tishler D.M., Weinberg Kl., Hinton D.R., et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36:1-6.
131. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003, 10:159-165.
132. van Vliet E., Aronica E., Redeker S., et al. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res. 2004, 60:203-213.
133. van Vliet E.A., Redeker S., Aronica E., et al. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 2005, 46:1569-1580.
134. van Vliet E.A., van Schaik R., Edelbroek P.M., et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47:672-680.
135. van Vliet E.A., van Schail R., Edelbroek P.M., et al. Region-specific over-expression of P-glycoprotein at the blood-brain-barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007, 322:141-147.
136. van Vliet E.A., Zibell G., Pekcec A., et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58:404-412.
137. Volk H.A., Potschka H., Löscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004, 58:67-79. http://www.ncbi.nlm.nih.gov/pubmed/15066676.
138. Volk H.A., Löscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005, 128:1358-1368.
139. Volk H.A., Arabadzisz D., Fritschy J.M., et al. Antiepileptc drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol Dis 2006, 21:633-646.
140. Vreugdenhil M., Wadman W.J. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 1999, 40:1512-1522.
141. Vreugdenhil M., van Veelen C.W., van Rijen P.C., et al. Effect of valproic acid on sodium currents in critical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res 1998, 32:309-320.
142. Wen T., Liu Y.C., Yang H.W., et al. Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J Neurol Sci 2008, 270:99-106.
143. Zibell G., Unkrüer B., Pekcec A., et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.
144. Zimprich F., Stogmann E., Bonelli S., et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 2008, 49:1109-1119.